IL-23 inhibitors in IBD
Risankizumab, mirikizumab and guselkumab in Crohn's disease and ulcerative colitis.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 8, 11, 12, 22, 35.
New guidelines and consensus this year
- Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's DiseaseJ Gastroenterol Hepatol2026 Jul
- [PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults]Rev Gastroenterol Peru2026 Apr-Jun
- S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situationsJ Dtsch Dermatol Ges2026 Feb
- AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's DiseaseGastroenterology2025 Dec
All papers from the last 12 months
214 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Long-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension StudyClin Transl Gastroenterol2026 Oct 14PMID 42873611
- Adherence to advanced therapies in inflammatory bowel diseases: Real-world rates and predictors of non-adherenceDig Liver Dis2026 Oct 9PMID 42855374
- Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysisInflamm Bowel Dis2026 Oct 8PMID 42850680
- EFFICACY AND SAFETY OF ADVANCED THERAPIES AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSISClin Gastroenterol Hepatol2026 Oct 6PMID 42838315Review
- Real-world effectiveness and predictors of need for extended induction of mirikizumab therapy in ulcerative colitisJ Can Assoc Gastroenterol2026 OctPMID 42840560
- Guselkumab as a therapeutic option for recalcitrant pyoderma gangrenosum and Crohn disease: a case report and review of the literatureSkin Health Dis2026 OctPMID 42813168
- Real-World Experience of Risankizumab in Refractory Pediatric Inflammatory Bowel DiseaseACG Case Rep J2026 OctPMID 42813147
- Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory DiseasesClin Pharmacokinet2026 OctPMID 42631819Systematic review
- Vulvar Crohn's-Case Series and Review of Treatment With UstekinumabJ Low Genit Tract Dis2026 Oct 1PMID 42519982Review
- Successful transition to mirikizumab following hepatic abscess during adalimumab therapy in a patient with ulcerative colitisClin J Gastroenterol2026 OctPMID 42503158
More gastroenterology trends
All specialties →MASLD and MASH
Metabolic dysfunction-associated steatotic liver disease and its new treatments.
Fecal microbiota transplantation
Transferring stool microbiota to treat C. difficile and other conditions.
Key point: Fecal microbiota-based therapies should be offered after treatment of a second recurrence of Clostridioides difficile infection.
EUS-guided interventions
Therapeutic procedures guided by endoscopic ultrasound.
Endoscopic bariatric therapy
Endoscopic sleeve gastroplasty and other endoscopic weight-loss procedures.
Early-onset colorectal cancer
Colorectal cancer in adults under 50.
Third-space endoscopy
Peroral endoscopic myotomy and endoscopic submucosal dissection.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(risankizumab[tiab] OR mirikizumab[tiab] OR guselkumab[tiab]) AND (Crohn[tiab] OR colitis[tiab] OR "inflammatory bowel"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.